PTC Therapeutics shared the below letter to the Duchenne community. We are pleased to see the results of the dystrophin study (Study 045) and thankful for PTC’s longtime commitment to the Duchenne community.
How to Identify and Manage Fat Embolism Syndrome (FES) in Fractures
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
Sarepta Therapeutics Announces Positive Data for Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
CureDuchenne Welcomes Patricia Brown as Senior Director of Community Engagement
Make an Impact
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.Donate